Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Revision label updated from v3.5.3 to v3.5.4, signalling a platform update. No study data or page content was changed.
    Difference
    0.1%
    Check dated 2026-05-15T05:29:18.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.5.3, signaling an updated site version. This update does not alter the study’s content or outcomes, and is a backend/version change rather than a content modification.
    Difference
    0.1%
    Check dated 2026-04-30T18:47:26.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    Revision: v3.5.2 was added and Revision: v3.5.0 was removed from the page.
    Difference
    0.1%
    Check dated 2026-04-16T10:55:22.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    Revision text updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-18T15:45:26.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    - Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T10:00:22.000Z thumbnail image
  8. Check
    104 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added, and the prior funding-status notice and Revision: v3.4.1 note were removed.
    Difference
    0.5%
    Check dated 2026-02-11T02:22:36.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.